Company / Total Assets
MoonLake Immunotherapeutics Total Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$424.4M
FY2025
5-year range
$9.7M / $526.5M
FY2021-FY2025
Trend
-11.2%
vs FY2024
Sector context
#153 of 214
Health Care
What the data says
At $424M, MoonLake Immunotherapeutics's total assets ranks #153 of 214 in the Health Care sector. Declined from $527M to $424M over the past 2 years.
Based on SEC 10-K filings.
$424M in FY2025 with a 5-year CAGR of +29.5%.
Declined from $527M to $424M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +76.8%
- 5-Year CAGR
- +29.5%
- 10-Year CAGR
- -
Sector benchmark
#153 of 214 in Health CareTop 71% of 214This company $424.4M Sector average $7.5B
▼
-94.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.5%, indicating consistent growth.
- In FY2025, total assets decreased 11.2% year-over-year.
- Ranks #153 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $424.4M | -11.2% |
| FY2024 | $477.9M | -9.2% |
| FY2023 | $526.5M | +585.2% |
| FY2022 | $76.8M | +693.6% |
| FY2021 | $9.7M | -91.7% |
| FY2020 | $116.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026